News | Contrast Media | September 11, 2015

Ultrasound Pilot Study Shows Positive Results for Treatment of Pancreatic Cancer

Microbubble contrast agent can improve tumor absorption of cancer drugs

ultrasound, microbubbles, delivery, absorption, drugs, pancreatic cancer, ICUS

September 11, 2015 — Tiny gas microbubbles can enhance the delivery and absorption of cancer drugs in patients with advanced pancreatic cancer, according to a new pilot study. The study was described at the International Contrast Ultrasound Society (ICUS) annual conference in Chicago.

One year after their last treatment cycle, two of 10 patients are still alive. 74 percent of pancreatic cancer patients die within the first year of diagnosis. The average life expectancy after diagnosis with metastic pancreatic cancer is just three to six months.

"Our early findings suggested that commercially-available ultrasound microbubbles, combined with a standard chemotherapy drug, might prolong survival in pancreatic cancer patients," according to Odd Helge Gilja, M.D., head of National Centre of Ultrasound in Gastroenterology at Haukeland University Hospital, in Bergen, Norway.

The pilot study included 10 patients with inoperable tumors, and preliminary results in 2014 showed that tumor size was reduced or growth was slowed in the patients, according to Gilja. "The patients treated with ultrasound sonoporation were able to undergo significantly more treatment cycles than those receiving standard chemotherapy. Additional studies are planned to confirm and potentially extend the results," he said.

"The findings are extremely exciting because this study appears to represent the first time ultrasound microbubbles have been used in patients for drug delivery," according to Steven Feinstein, M.D., co-president of ICUS and a professor of medicine at Rush University, Chicago. "If further studies confirm the Bergen findings, ultrasound microbubbles could prove to be an innovative platform option for delivery of drugs and genes to treat other cancers and a wide variety of medical abnormalities throughout the body," he said.

Gilja reported that all 10 patients who participated in the pilot Phase I study received an infusion of a standard chemotherapy drug, gemcitabine, followed by an infusion of a microbubble contrast agent. A customized commercial ultrasound scanner was then used to confirm the presence of the microbubbles in the vicinity of the tumor and to induce "sonoporation," a transient opening and resealing of cell membranes to allow for enhanced delivery and absorption of the cancer drug. Tumor sizes were confirmed by computed tomography (CT) imaging, according to Gilja.

Three ultrasound contrast agents — Definity (Lantheus Medical Imaging), Optison (GE Healthcare) and Lumason (Bracco Diagnostics) — are available in the United States but are approved by the U.S. Food and Drug Administration for cardiac imaging only.

For more information: www.icus-society.org

Related Content

The Revolution Apex intelligent computed tomography (CT) scanner

The Revolution Apex intelligent computed tomography (CT) scanner. Image courtesy of GE Healthcare.

News | RSNA | October 18, 2019
At the 2019 annual meeting of the Radiological Society of North America (RSNA 2019), Dec. 1-6 in Chicago, GE Healthcare...
Philips Partners With PURE on Tele-Ultrasound Program for Physicians in Rwanda
News | Ultrasound Imaging | October 09, 2019
Philips and non-profit organization PURE (Point-of-care Ultrasound in Resource-limited Environments) highlighted a tele...
Samsung to Unveil Hera I10 Ultrasound at SDMS 2019
Technology | Ultrasound Women's Health | September 28, 2019
NeuroLogica, a subsidiary of Samsung Electronics Co. Ltd., announced that the Samsung Hera I10 ultrasound system has...
Fujifilm Sonosite Partnering With Artificial Intelligence Incubator to Improve Ultrasound Image Interpretation
News | Ultrasound Imaging | September 23, 2019
Fujifilm SonoSite Inc. and the Allen Institute of Artificial Intelligence (AI2) Incubator, builder of AI-first startups...
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...
Characteristics nephrologists associate with renal high-risk patients. (n=13)

Characteristics nephrologists associate with renal high-risk patients. (n=13)

Feature | Contrast Media | September 05, 2019
The global rise in chronic disease has significantly increased demand for diagnostic imaging procedures, and in turn,
Medical Imaging Rates Continue to Rise Despite Push to Reduce Their Use
News | Radiology Imaging | September 03, 2019
Despite a broad campaign among physician groups to reduce the amount of medical imaging, use rates of various scans...
News | Contrast Media | September 03, 2019
Researchers in South Korea have found that patients with family and personal history of allergic reactions to contrast...
Philips Debuts Cardiac Ultrasound and Enterprise Informatics Offerings at ESC 2019
News | Cardiac Imaging | August 30, 2019
Philips will showcase its latest cardiac care innovations at the European Society of Cardiology (ESC) Congress 2019,...